See more : Enstar Group Limited (ESGRO) Income Statement Analysis – Financial Results
Complete financial analysis of Athenex, Inc. (ATNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athenex, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BCL Industries Limited (BCLIL.BO) Income Statement Analysis – Financial Results
- Enthusiast Gaming Holdings Inc. (EGLX) Income Statement Analysis – Financial Results
- Cambria Automobiles plc (CAMB.L) Income Statement Analysis – Financial Results
- Tenth Avenue Petroleum Corp. (URXZF) Income Statement Analysis – Financial Results
- Sinopec Shanghai Petrochemical Company Limited (0338.HK) Income Statement Analysis – Financial Results
Athenex, Inc. (ATNX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.athenex.com
About Athenex, Inc.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 102.82M | 120.18M | 144.39M | 101.23M | 89.10M | 38.04M | 20.55M | 13.94M |
| Cost of Revenue | 76.12M | 82.41M | 95.36M | 69.62M | 47.01M | 25.12M | 19.72M | 13.15M |
| Gross Profit | 26.70M | 37.78M | 49.04M | 31.61M | 42.10M | 12.92M | 833.00K | 791.00K |
| Gross Profit Ratio | 25.97% | 31.43% | 33.96% | 31.23% | 47.24% | 33.96% | 4.05% | 5.67% |
| Research & Development | 51.76M | 80.20M | 75.90M | 84.39M | 119.91M | 76.80M | 60.62M | 24.46M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 44.88M | 72.55M | 96.86M | 66.75M | 49.01M | 46.11M | 25.96M | 27.04M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 19.71M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 96.64M | 152.75M | 172.76M | 151.14M | 168.91M | 122.91M | 86.58M | 51.50M |
| Cost & Expenses | 172.76M | 235.16M | 268.11M | 220.76M | 215.92M | 148.03M | 106.30M | 64.65M |
| Interest Income | 363.00K | 227.00K | 874.00K | 1.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.84M | 20.74M | 11.22M | 6.95M | 1.79M | 5.91M | 1.89M | 1.00K |
| Depreciation & Amortization | 363.00K | 227.00K | 874.00K | 1.88M | 3.27M | 3.67M | 2.03M | 888.00K |
| EBITDA | -69.57M | -114.75M | -122.85M | -117.65M | -112.28M | -121.50M | -84.06M | -49.77M |
| EBITDA Ratio | -67.66% | -95.48% | -85.08% | -116.22% | -126.01% | -319.38% | -409.05% | -356.89% |
| Operating Income | -69.94M | -114.98M | -123.72M | -119.53M | -126.82M | -109.99M | -85.75M | -50.71M |
| Operating Income Ratio | -68.02% | -95.67% | -85.69% | -118.08% | -142.33% | -289.11% | -417.24% | -363.65% |
| Total Other Income/Expenses | -28.69M | -89.93M | -20.62M | -5.07M | -1.79M | -21.32M | -2.42M | -1.00K |
| Income Before Tax | -98.63M | -204.91M | -144.35M | -124.61M | -128.61M | -131.31M | -88.17M | -50.71M |
| Income Before Tax Ratio | -95.92% | -170.50% | -99.97% | -123.09% | -144.34% | -345.16% | -429.04% | -363.66% |
| Income Tax Expense | 347.00K | -10.60M | 4.09M | 928.00K | 100.00K | 85.00K | -265.00K | -54.00K |
| Net Income | -98.98M | -194.31M | -148.43M | -125.53M | -117.44M | -131.17M | -87.72M | -50.60M |
| Net Income Ratio | -96.26% | -161.68% | -102.80% | -124.01% | -131.81% | -344.79% | -426.82% | -362.88% |
| EPS | -15.13 | -37.39 | -34.89 | -33.90 | -36.40 | -45.06 | -41.51 | -21.77 |
| EPS Diluted | -15.13 | -37.39 | -34.89 | -33.90 | -36.40 | -45.06 | -41.51 | -21.77 |
| Weighted Avg Shares Out | 6.54M | 5.20M | 4.25M | 3.70M | 3.23M | 2.91M | 2.11M | 2.32M |
| Weighted Avg Shares Out (Dil) | 6.54M | 5.20M | 4.25M | 3.70M | 3.23M | 2.91M | 2.11M | 2.32M |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
MAY 3, 2021 ATNX INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.
ATNX Final Deadline Tomorrow: Rosen, A Longstanding Law Firm, Encourages Athenex, Inc. Investors with Losses over $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action - ATNX
ATNX Final Deadline Tomorrow: Rosen, A Longstanding Law Firm, Encourages Athenex, Inc. Investors with Losses over $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action - ATNX
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX
ATNX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Athenex, Inc.
ATNX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Athenex, Inc.
Source: https://incomestatements.info
Category: Stock Reports